Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert J Ferrante

Showing results (31-40 of 81) with videos related to

Pageof 9
Sort By:
Journal of Medicinal Chemistry|July 18, 2015
Tertiary Amine Pyrazolones and Their Salts as Inhibitors of Mutant Superoxide Dismutase 1-Dependent Protein Aggregation for the Treatment of Amyotrophic Lateral SclerosisYinan Zhang, Kevin Tianmeng Zhao, Susan G Fox, et al.
Journal of Medicinal Chemistry|December 24, 2011
ADME-guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: potential application for the treatment of amyotrophic lateral sclerosisTian Chen, Radhia Benmohamed, Jinho Kim, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 22, 2003
Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's diseaseXin Wang, Shan Zhu, Martin Drozda, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 5, 2006
ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's diseaseHoon Ryu, Junghee Lee, Sean W Hagerty, et al.
Neurobiology of Disease|November 22, 2005
Mice lacking alpha-synuclein are resistant to mitochondrial toxinsPeter Klivenyi, Donald Siwek, Gabrielle Gardian, et al.
Journal of Neurochemistry|September 2, 2005
Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's diseaseBruce G Jenkins, Ole A Andreassen, Alpaslan Dedeoglu, et al.
The Journal of Comparative Neurology|August 30, 2005
Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic miceEdward C Stack, James K Kubilus, Karen Smith, et al.
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases|July 12, 2008
Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis miceSteven J Del Signore, Daniel J Amante, Jinho Kim, et al.
Bioorganic & Medicinal Chemistry|November 25, 2010
Arylsulfanyl pyrazolones block mutant SOD1-G93A aggregation. Potential application for the treatment of amyotrophic lateral sclerosisTian Chen, Radhia Benmohamed, Anthony C Arvanites, et al.
ACS Medicinal Chemistry Letters|March 25, 2017
Correction to "Chiral Cyclohexane 1,3-Diones as Inhibitors of Mutant SOD1-Dependent Protein Aggregation for the Treatment of ALS"Yinan Zhang, Radhia Benmohamed, Wei Zhang, et al.
Pageof 9

Showing results (31-40 of 81) with videos related to

Sort By:
Pageof 9
Journal of Medicinal Chemistry|July 18, 2015
Tertiary Amine Pyrazolones and Their Salts as Inhibitors of Mutant Superoxide Dismutase 1-Dependent Protein Aggregation for the Treatment of Amyotrophic Lateral SclerosisYinan Zhang, Kevin Tianmeng Zhao, Susan G Fox, et al.
Journal of Medicinal Chemistry|December 24, 2011
ADME-guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: potential application for the treatment of amyotrophic lateral sclerosisTian Chen, Radhia Benmohamed, Jinho Kim, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 22, 2003
Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's diseaseXin Wang, Shan Zhu, Martin Drozda, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 5, 2006
ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's diseaseHoon Ryu, Junghee Lee, Sean W Hagerty, et al.
Neurobiology of Disease|November 22, 2005
Mice lacking alpha-synuclein are resistant to mitochondrial toxinsPeter Klivenyi, Donald Siwek, Gabrielle Gardian, et al.
Journal of Neurochemistry|September 2, 2005
Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's diseaseBruce G Jenkins, Ole A Andreassen, Alpaslan Dedeoglu, et al.
The Journal of Comparative Neurology|August 30, 2005
Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic miceEdward C Stack, James K Kubilus, Karen Smith, et al.
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases|July 12, 2008
Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis miceSteven J Del Signore, Daniel J Amante, Jinho Kim, et al.
Bioorganic & Medicinal Chemistry|November 25, 2010
Arylsulfanyl pyrazolones block mutant SOD1-G93A aggregation. Potential application for the treatment of amyotrophic lateral sclerosisTian Chen, Radhia Benmohamed, Anthony C Arvanites, et al.
ACS Medicinal Chemistry Letters|March 25, 2017
Correction to "Chiral Cyclohexane 1,3-Diones as Inhibitors of Mutant SOD1-Dependent Protein Aggregation for the Treatment of ALS"Yinan Zhang, Radhia Benmohamed, Wei Zhang, et al.
Pageof 9